Research Papers: Sensing

Detection of capecitabine (Xeloda®) on the skin surface after oral administration

[+] Author Affiliations
Mao-Dong Huang, Stefan Florek

Leibniz-Institut für Analytische Wissenschaften–ISAS–e. V., Albert-Einstein-Straße 9, 12489 Berlin, Germany

Harald Fuss

Helios Klinikum, Department of Hematology, Oncology and Palliative Care, Pieskower Street 33, 15526 Bad Saarow-Pieskow, Germany

Jürgen Lademann, Alexa Patzelt, Martina C. Meinke, Sora Jung

Charité–Universitätsmedizin Berlin, Center of Experimental and Applied Cutaneous Physiology, Department of Dermatology, Venereology and Allergology, Charitéplatz1, 10117 Berlin, Germany

J. Biomed. Opt. 21(4), 047002 (Apr 26, 2016). doi:10.1117/1.JBO.21.4.047002
History: Received December 28, 2015; Accepted April 1, 2016
Text Size: A A A

Abstract.  Palmoplantar erythrodysesthesia (PPE), or hand-foot syndrome, is a cutaneous toxicity under various chemotherapeutics contributing to the most frequent side effects in patients treated with capecitabine (Xeloda®). The pathomechanism of PPE has been unclear. Here, the topical detection of capecitabine in the skin after oral application was shown in 10 patients receiving 2500  mg/m2/day capecitabine. Sweat samples were taken prior to and one week after oral administration of capecitabine. Using high-resolution continuum source absorption spectrometry, the changes in concentrations of fluorine, which is an ingredient of capecitabine, were quantified and statistically analyzed. Here, we show an increase in fluorine concentrations from 40±10  ppb (2±0.5  pM) before capecitabine administration to 27.7±11.8  ppm (14.6±6.5  nM) after application, p<0.001. The results show the secretion of capecitabine on the skin surface after oral administration, indicating a local toxic effect as a possible pathomechanism of PPE.

Figures in this Article
© 2016 Society of Photo-Optical Instrumentation Engineers

Citation

Mao-Dong Huang ; Harald Fuss ; Jürgen Lademann ; Stefan Florek ; Alexa Patzelt, et al.
"Detection of capecitabine (Xeloda®) on the skin surface after oral administration", J. Biomed. Opt. 21(4), 047002 (Apr 26, 2016). ; http://dx.doi.org/10.1117/1.JBO.21.4.047002


Tables

Access This Article
Sign in or Create a personal account to Buy this article ($20 for members, $25 for non-members).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Related Book Chapters

Topic Collections

PubMed Articles
Advertisement


 

  • Don't have an account?
  • Subscribe to the SPIE Digital Library
  • Create a FREE account to sign up for Digital Library content alerts and gain access to institutional subscriptions remotely.
Access This Article
Sign in or Create a personal account to Buy this article ($20 for members, $25 for non-members).
Access This Proceeding
Sign in or Create a personal account to Buy this article ($15 for members, $18 for non-members).
Access This Chapter

Access to SPIE eBooks is limited to subscribing institutions and is not available as part of a personal subscription. Print or electronic versions of individual SPIE books may be purchased via SPIE.org.